Long-Term Phase 3 Data Show ADUHELM® Continues to Reduce Underlying Pathologies of Alzheimer’s Disease in Patients Treated for More Than Two Years
March 16, 2022 07:30 ET
|
Biogen Inc.
ADUHELM continued to reduce two key Alzheimer’s disease pathologies, amyloid beta plaques and p-tau181, in patients treated for up to two and a half yearsData from both Phase 3 studies also show that...
Biogen and Eisai amend collaboration agreements on Alzheimer’s disease treatments
March 14, 2022 19:00 ET
|
Biogen Inc.
Aducanumab collaboration to convert from Eisai sharing of global profits and losses to a global royalty arrangement, effective January 1, 2023Lecanemab collaboration to continue unchanged...
Biogen Announces New Updates Across its SMA Research Program at 2022 MDA Conference
March 14, 2022 07:30 ET
|
Biogen Inc.
First patient treated in the ASCEND study evaluating the potential benefit of investigational higher dose nusinersen in children, teens and adults previously treated with Evrysdi® (risdiplam)Baseline...
Biogen to Present New Research at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD 2022)
March 11, 2022 16:30 ET
|
Biogen Inc.
CAMBRIDGE, Mass., March 11, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the company will present new Alzheimer’s disease research, as well as data for ADUHELM® (aducanumab-avwa)...
Biogen and Xbrane Announce Commercialization and License Agreement for Proposed Biosimilar Referencing CIMZIA® (Certolizumab pegol) with the Potential to Treat Rheumatoid Arthritis
February 07, 2022 16:05 ET
|
Biogen Inc.
CAMBRIDGE, Mass and SOLNA, Sweden, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Xbrane Biopharma AB (STO: XBRANE) today announced that they have entered into a commercialization...
Biogen Exercises Option to Participate in the Development and Commercialization of a Late-Stage Bispecific Antibody
February 01, 2022 07:30 ET
|
Biogen Inc.
Mosunetuzumab is an investigational T-cell engaging bispecific antibody targeting CD20 and CD3 in development for B-cell non-Hodgkin’s lymphoma and other therapeutic areas CAMBRIDGE, Mass., Feb. 01,...
Biogen Announces Nancy Leaming and Brian Posner to Retire from Board of Directors
January 31, 2022 07:30 ET
|
Biogen Inc.
CAMBRIDGE, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that Nancy Leaming and Brian Posner will retire from Biogen’s Board of Directors, effective at the time...
Biogen Reaches Agreement with Samsung Biologics to Sell Equity Stake in Their Biosimilar Joint Venture for up to $2.3 billion
January 27, 2022 18:50 ET
|
Biogen Inc.
CAMBRIDGE, Mass., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that they have entered into an agreement whereby Samsung Biologics will acquire Biogen’s equity stake in...
Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM®
January 27, 2022 07:30 ET
|
Biogen Inc.
CAMBRIDGE, Mass., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced additional details about the Phase 4 post-marketing confirmatory...
Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA
January 04, 2022 07:34 ET
|
Biogen Inc.
BIIB115 is a preclinical investigational antisense oligonucleotide (ASO) that may have the potential for extended dosing intervalsBiogen paid Ionis a $60 million one-time upfront payment CAMBRIDGE,...